IL15 and neoplasm: Prior to this advancement, IL‐15, a cytokine recognized for promoting T cell survival and function, had been integrated into CAR‐T cell therapy to enhance anti‐tumor activity.[109] Professor Andras Heczey and colleagues were the first to validate the efficacy of IL‐15‐enhanced CAR‐T cells in human clinical trials.